Your session is about to expire
← Back to Search
laboratory biomarker analysis for Lymphoma
Study Summary
This trial will compare PET-directed chemotherapy to standard chemotherapy in treating patients with limited-stage diffuse large B-cell lymphoma.
- Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Patients with a specific type of lymphoma called limited-stage DLBCL, which can be measured or evaluated.The type of CT scans used for this study must be of higher quality and show clear details.You have primary mediastinal lymphoma or testicular lymphoma, which means you cannot participate.
- Group 1: PET Negative: R-CHOP
- Group 2: PET Positive: IFRT +Zevalin
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 30 Other Conditions - This treatment demonstrated efficacy for 30 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What objectives does laboratory biomarker analysis typically serve?
"Laboratory biomarker analysis is a helpful tool for treating various illnesses, including lung cancer, small cell lung cancer (SCLC), thyroiditis, and polyangium."
Is there still availability for prospective participants in this experiment?
"At present, this medical trial is not accepting participants. It was initially posted on September 1st 2011 and last updated on July 6th 2022. However, there are a multitude of other trials currently recruiting - 1749 involving lymphoma patients and 1427 focused on laboratory biomarker analysis."
Are there any American healthcare facilities conducting this research investigation?
"At the Island Hospital Cancer Care Center in Anacortes, Washington, Gibbs Regional Cancer Center at Spartanburg Regional Medical Centre and the Cancer Center of Kansas - Wellington are all sites offering this trial. In addition to these locations there are a further 100 clinics participating."
What earlier experiments have been done to investigate laboratory biomarker metrics?
"Currently, there are 1427 clinical trials that focus on laboratory biomarker analysis with 311 of those in Phase 3. Whilst the majority is based out of Bethesda, Maryland, over 51726 locations across the world are running studies associated to this treatment."
What is the scope of participants in this experiment?
"Unfortunately, this trial is not presently accepting candidates. The initial posting was made on September 1st 2011 and the last update occurred July 6th 2022. On a positive note, there are currently 1749 clinical trials searching for lymphoma patients and 1427 laboratory biomarker studies actively seeking participants to join their research efforts."
Are the results from laboratory biomarker analysis officially validated by the FDA?
"Our team at Power gave laboratory biomarker analysis a score of 2 on the 1 to 3 scale, as there is ample data proving its safety but no existing evidence that it works effectively."
Share this study with friends
Copy Link
Messenger